Cargando…
109 Problems and prospects of development of the subunit TB vaccine
Tuberculosis (TB) causes about 1.4 million deaths each year. Currently the only licensed anti-tuberculosis vaccine is Bacille Calmette-Guérin (BCG). This live attenuated vaccine has been in use for over 80 years and has displayed up to 80% efficacy against serious forms of the disease, eg, meningiti...
Autores principales: | Tkachuk, A.B., Lunin, V.G., Karyagina, A.S., Gintsburg, A.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149670/ http://dx.doi.org/10.1097/01.qai.0000446689.08492.a0 |
Ejemplares similares
-
Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
por: Tkachuk, A. P., et al.
Publicado: (2017) -
S109. SYMPTOM NETWORK MODELS OF PSYCHOSIS
por: Isvoranu, Adela-Maria
Publicado: (2018) -
A Novel Approach to the Development of Anticarcinogenic Vaccines
por: Glushkov, A.N., et al.
Publicado: (2010) -
Pseudomonas Aeruginosa Lectins As Targets for Novel Antibacterials
por: Grishin, A. V., et al.
Publicado: (2015) -
First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment
por: Vasina, Daria V., et al.
Publicado: (2019)